FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034992158> ?p ?o ?g. }

• W2034992158 endingPage "31" @default.
• W2034992158 startingPage "25" @default.
• W2034992158 abstract "Background: Psoriasis substantially impairs the health‐related quality of life (HRQOL) of patients, and a comprehensive evaluation of treatment includes HRQOL measures. Objective: To assess the impact of adalimumab on patient‐reported outcomes (PROs) of patients with moderate to severe psoriasis. Methods: In a Phase II, randomized, controlled trial, the efficacy and safety of two dosages of adalimumab (40 mg weekly or every other week) versus placebo were assessed for 12 weeks in the treatment of moderate to severe plaque psoriasis. Patients completed the Dermatology Life Quality Index (DLQI), Short‐Form 36 (SF‐36) Health Survey, and EuroQOL‐5D (EQ‐5D) at baseline and 12 weeks. The primary endpoint was the percentage of patients achieving a ⩾75% reduction in the Psoriasis Area and Severity Index score (PASI 75). Investigators assessed PASI and Physician's Global Assessment (PGA) scores. Results: Adalimumab patients (either dosage) displayed significantly greater improvements versus placebo patients in DLQI, EQ‐5D, and SF‐36 Mental Component Summary scores, as well as in Bodily Pain, Vitality, Social Functioning, Role–Emotional, and Mental Health domains. The adalimumab 40‐mg weekly group also reported significantly greater improvements in SF‐36 Physical Component Summary scores versus the placebo group. Conclusion: Both adalimumab dosages were efficacious in improving dermatology‐specific and general PROs in patients with moderate to severe psoriasis." @default.
• W2034992158 created "2016-06-24" @default.
• W2034992158 creator A5001054264 @default.
• W2034992158 creator A5012239975 @default.
• W2034992158 creator A5018964407 @default.
• W2034992158 creator A5020627620 @default.
• W2034992158 creator A5059354904 @default.
• W2034992158 creator A5061849637 @default.
• W2034992158 date "2007-01-01" @default.
• W2034992158 modified "2023-10-18" @default.
• W2034992158 title "Adalimumab treatment is associated with improvement in health‐related quality of life in psoriasis: Patient‐reported outcomes from a Phase II randomized controlled trial" @default.
• W2034992158 cites W1519400268 @default.
• W2034992158 cites W1945023269 @default.
• W2034992158 cites W1978428707 @default.
• W2034992158 cites W1980773105 @default.
• W2034992158 cites W2008716526 @default.
• W2034992158 cites W2012581664 @default.
• W2034992158 cites W2012608901 @default.
• W2034992158 cites W2019205814 @default.
• W2034992158 cites W2034585843 @default.
• W2034992158 cites W2038114578 @default.
• W2034992158 cites W2038741370 @default.
• W2034992158 cites W2039456416 @default.
• W2034992158 cites W2041499523 @default.
• W2034992158 cites W2042893181 @default.
• W2034992158 cites W2043469120 @default.
• W2034992158 cites W2080165152 @default.
• W2034992158 cites W2081730357 @default.
• W2034992158 cites W2091442391 @default.
• W2034992158 cites W2096991001 @default.
• W2034992158 cites W2112031699 @default.
• W2034992158 cites W2122897116 @default.
• W2034992158 cites W2129412675 @default.
• W2034992158 cites W2145628010 @default.
• W2034992158 cites W2146050736 @default.
• W2034992158 cites W2164533070 @default.
• W2034992158 cites W2168564353 @default.
• W2034992158 cites W2168911501 @default.
• W2034992158 cites W2473786944 @default.
• W2034992158 doi "https://doi.org/10.1080/09546630601121060" @default.
• W2034992158 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17365264" @default.
• W2034992158 hasPublicationYear "2007" @default.
• W2034992158 type Work @default.
• W2034992158 sameAs 2034992158 @default.
• W2034992158 citedByCount "77" @default.
• W2034992158 countsByYear W20349921582012 @default.
• W2034992158 countsByYear W20349921582013 @default.
• W2034992158 countsByYear W20349921582014 @default.
• W2034992158 countsByYear W20349921582015 @default.
• W2034992158 countsByYear W20349921582016 @default.
• W2034992158 countsByYear W20349921582017 @default.
• W2034992158 countsByYear W20349921582018 @default.
• W2034992158 countsByYear W20349921582019 @default.
• W2034992158 countsByYear W20349921582020 @default.
• W2034992158 countsByYear W20349921582021 @default.
• W2034992158 countsByYear W20349921582022 @default.
• W2034992158 countsByYear W20349921582023 @default.
• W2034992158 crossrefType "journal-article" @default.
• W2034992158 hasAuthorship W2034992158A5001054264 @default.
• W2034992158 hasAuthorship W2034992158A5012239975 @default.
• W2034992158 hasAuthorship W2034992158A5018964407 @default.
• W2034992158 hasAuthorship W2034992158A5020627620 @default.
• W2034992158 hasAuthorship W2034992158A5059354904 @default.
• W2034992158 hasAuthorship W2034992158A5061849637 @default.
• W2034992158 hasConcept C126322002 @default.
• W2034992158 hasConcept C142724271 @default.
• W2034992158 hasConcept C159110408 @default.
• W2034992158 hasConcept C16005928 @default.
• W2034992158 hasConcept C162156334 @default.
• W2034992158 hasConcept C168563851 @default.
• W2034992158 hasConcept C1862650 @default.
• W2034992158 hasConcept C203092338 @default.
• W2034992158 hasConcept C204787440 @default.
• W2034992158 hasConcept C27081682 @default.
• W2034992158 hasConcept C2776173921 @default.
• W2034992158 hasConcept C2776237627 @default.
• W2034992158 hasConcept C2777011040 @default.
• W2034992158 hasConcept C2779134260 @default.
• W2034992158 hasConcept C2779951463 @default.
• W2034992158 hasConcept C2780132546 @default.
• W2034992158 hasConcept C2780564577 @default.
• W2034992158 hasConcept C30036603 @default.
• W2034992158 hasConcept C3019006561 @default.
• W2034992158 hasConcept C71924100 @default.
• W2034992158 hasConceptScore W2034992158C126322002 @default.
• W2034992158 hasConceptScore W2034992158C142724271 @default.
• W2034992158 hasConceptScore W2034992158C159110408 @default.
• W2034992158 hasConceptScore W2034992158C16005928 @default.
• W2034992158 hasConceptScore W2034992158C162156334 @default.
• W2034992158 hasConceptScore W2034992158C168563851 @default.
• W2034992158 hasConceptScore W2034992158C1862650 @default.
• W2034992158 hasConceptScore W2034992158C203092338 @default.
• W2034992158 hasConceptScore W2034992158C204787440 @default.
• W2034992158 hasConceptScore W2034992158C27081682 @default.
• W2034992158 hasConceptScore W2034992158C2776173921 @default.
• W2034992158 hasConceptScore W2034992158C2776237627 @default.
• W2034992158 hasConceptScore W2034992158C2777011040 @default.
• W2034992158 hasConceptScore W2034992158C2779134260 @default.

• next